Intestinal Ralstonia pickettii augments glucose intolerance in obesity
An altered intestinal microbiota composition has been implicated in the pathogenesis of metabolic disease including obesity and type 2 diabetes mellitus (T2DM). Low grade inflammation, potentially initiated by the intestinal microbiota, has been suggested to be a driving force in the development of...
Saved in:
Published in | PloS one Vol. 12; no. 11; p. e0181693 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
22.11.2017
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
ISSN | 1932-6203 1932-6203 |
DOI | 10.1371/journal.pone.0181693 |
Cover
Summary: | An altered intestinal microbiota composition has been implicated in the pathogenesis of metabolic disease including obesity and type 2 diabetes mellitus (T2DM). Low grade inflammation, potentially initiated by the intestinal microbiota, has been suggested to be a driving force in the development of insulin resistance in obesity. Here, we report that bacterial DNA is present in mesenteric adipose tissue of obese but otherwise healthy human subjects. Pyrosequencing of bacterial 16S rRNA genes revealed that DNA from the Gram-negative species Ralstonia was most prevalent. Interestingly, fecal abundance of Ralstonia pickettii was increased in obese subjects with pre-diabetes and T2DM. To assess if R. pickettii was causally involved in development of obesity and T2DM, we performed a proof-of-concept study in diet-induced obese (DIO) mice. Compared to vehicle-treated control mice, R. pickettii-treated DIO mice had reduced glucose tolerance. In addition, circulating levels of endotoxin were increased in R. pickettii-treated mice. In conclusion, this study suggests that intestinal Ralstonia is increased in obese human subjects with T2DM and reciprocally worsens glucose tolerance in DIO mice. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: We have the following interests. This study was partly funded by AFA insurances. M.N. and W.M.deV. are founders, own equity and are in the Scientific Advisory Board of Caelus Pharmaceuticals, the Netherlands; WMdV is in the Scientific Advisory Board of Chr Hansen Horsholm Danmark and the M.N. and W.M.deV. are founders, own equity and are in the Scientific Advisory Board of Caelus Pharmaceutical(NIHS) Lausanne Switzerland. F.B. is a founder of MetaboGen AB, Sweden. F.B. and G.B own equity in MetaboGen AB, Sweden. None of these are directly relevant to the current paper. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0181693 |